• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Active Biotech - Articles and news items

laquinimod

Patient enrollment in Phase III CONCERTO trial of laquinimod completed

Industry news / 25 June 2015 / Victoria White

The patient enrollment for the Phase III CONCERTO trial of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) has been finalised…

laquinimod

First patient enrolled in Phase II study evaluating laquinimod for primary progressive MS

Industry news / 24 April 2015 / Victoria White

The first patient has been enrolled in a Phase II study evaluating laquinimod, an investigational, oral, immune modulator, for the treatment of PPMS…

prostate-cancer-tasquinimod

Active Biotech and Ipsen discontinue the development of prostate cancer drug tasquinimod

Industry news / 16 April 2015 / Victoria White

Active Biotech and Ipsen discontinue the development of prostate cancer drug tasquinimod and have released top line results for the 10TASQ10 study…

TEVA LOGO

New data presented at 29th ECTRIMS Congress reinforce the clinical profile of investigational laquinimod on disease progression and inflammation in relapsing-remitting multiple sclerosis

Industry news / 4 October 2013 / Teva Pharmaceutical Industries Ltd

Pooled data analysis of Phase III ALLEGRO and BRAVO studies add to our understanding of investigational laquinimod for relapsing-remitting Multiple Sclerosis…

TEVA LOGO

Phase IIa laquinimod trial results show positive data for potential use in active crohn’s disease

Industry news, News / 22 October 2012 / Teva Pharmaceutical Industries Ltd

TEVA and Active Biotech announced the presentation of Phase IIa clinical data…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +